Broadcast Live   |   Upload & Publish  | About  | Register  | Sign in
E-mail:
Password:
Remember me on this computer
You need to install or upgrade your Flash Player!

3B NEXUS video platform & portal supports the latest version of Macromedia Flash player.


3B PLAYER by 3B NEXUS

Close [ X ]
Copy this code to embed & stream this video on your website
 
Copy this URL to share or create a link back to this video
Dr. Thomas Höger
Chief Executive Officer / CFO
Germany
Apogenix: APG101 – A Novel Approach for the Treatment of Cancer
APG101 is a human fusion protein consisting of the extracellular domain of the CD95 receptor fused to the IgG part of an antibody. It binds to the CD95 ligand, thereby blocking the interaction with its cognate receptor. Whereas this interaction triggers apoptosis in many cells, it stimulates invasive growth in cancer cells. Blocking CD95 mediated tumor growth thus represents a novel concept to treating cancer.

[ close ] 
Please select the appropriate option to comply with legal regulations

Individual Investor Professional Investor or Financial Advisor
This multimedia channel includes videos, webcasts and live broadcasts suitable for members of the general public over 18 years of age and not engaged in providing investment advice. Access this channel for personal interest & information only. This multimedia channel includes investor videos and webcast presentations, live broadcasts and documents intended only for authorised and regulated professionals and financial advisers eligible to provide investment advice to private investors.
I comply with these terms I comply with these terms
Remember my choice for all channels on this portal Enter Media Channel »
No reliance should be placed on the information on this site which may change without notice.
You should read the Terms & Conditions section before browsing this site.

Search in Sort By
1 2 3 4 of 4   MORE   SHOW
  Select a title or search in slides to skip chapters
00:00
Apogennix CD95 Ligand Inhibitor APG101, CD95 Ligand Inhibitor APG101 - A Novel Approach for the Treatment of Cancer
00:18
Company Overview, Company Overview
01:25
CD95L inhibitor , APG101 First-in-class CD95L inhibitor for the treatment of cancer
01:38
receptor Fc-fusion protein, Glioblastoma, Myelodysplastic , APG101 - The Product
02:50
Apoptosis, Ligand, Mode of Action
04:14
tumors, prognostic , What is the role of the CD95L/CD95 system in cancer?
04:31
Susanne Kleber, inhibitors , CD95 in Cancer
05:27
CD95 Ligand, Tumor , Mode of Action in Cancer
05:58
Glioblastoma, parenchyma, Temodar, glioblastoma , Glioblastoma - Disease & Application
07:38
glioblastoma, CD95 and CD95, CD95L , Glioblastoma - Scientific Rationale
08:17
glioblastoma in vivo, Preclinical, Proof, survival, Glioblastoma - Preclinical
09:04
Glioblastoma, APG101, Glioblastoma - APG101 Reaches Target in Tumor Patients
09:56
placebo-controlled, Clinical Phase I, APG101 - Clinical Phase I
10:16
Clinical Phase II, Study Design, temozolomide , Glioblastoma - Clinical Phase II
11:23
Milestones, primary endpoint, proof of concept, Next Milestones
12:07
TRAIL Receptor Agonists, hexameric, TRAIL/Fc fusion, efficacy, Apoptotic , TRAIL Receptor Agonists
13:55
, Acknowledgements